PXDN

Across TCGA pan-cancer cohorts, PXDN RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated PXDN data layer compared with 14 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher PXDN RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PXDN expression acts as an unfavorable survival marker, although some lineages such as UCS and LAML show a favorable association.

UVM, MESO, and BLCA are the cancer types where PXDN RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Median	II,III,IV	0.427	0.741	<.001	133	view →
MESO	OS	Median	All	0.249	0.510	<.001	117	view →
BLCA	OS	Quartile	All	0.521	0.747	<.001	88	view →
STAD	OS	Tertile	All	0.310	0.572	<.001	77	view →
CESC	DFS	Median	All	0.759	0.882	<.001	58	view →
ACC	DFS	Tertile	All	0.176	0.694	<.001	42	view →
UCEC	DFS	Quartile	All	0.576	0.777	.003	38	view →
LGG	DFS	Median	All	0.782	0.879	<.001	37	view →
OV	OS	Median	III,IV	0.269	0.365	.004	32	view →
UCS	OS	Tertile	III,IV	0.609	0.206	.012	30	view →
SARC	OS	Median	All	0.668	0.818	.001	29	view →
LUSC	DFS	Quartile	All	0.702	0.818	.010	27	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

PXDN–UVM (DFS)

Open the UVM breakdown →